4 completed, 2 terminated, 1 active not recruiting, 1 not yet recruiting. 9 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 4, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 2, Not yet recruiting 1, Withdrawn 1 |
Follow Small Cell Carcinoma: new trials by email Literature Review of Small Cell Carcinoma trials Research Report on Small Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer Tarlatamab, Sacituzumab Govitecan - Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2026-04-25 | 2026-04-28 | |
| Penfluridol for Relapsed/Refractory Small Cell Cancers Penfluridol Monotherapy for Relapsed/Refractory Small-Cell Lung or Cervical Cancer - Small Cell Carcinoma, Small Cell Carcinoma of Lung | Phase 1 / Phase 2 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 33 | 2025-10-01 | 2025-10-03 |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | Phase 2 | Terminated | MacroGenics | 192 | 2023-06-13 | 2026-02-09 |
| Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer Apalutamide, Cetrelimab - Small Cell Neuroendocrine Carcinoma, Prostate Cancer | Phase 2 | Terminated | Rahul Aggarwal | 2 | 2022-03-16 | 2025-05-15 |
| A Trial of Talabostat (BXCL701) and Pembrolizumab in Participants With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype Talabostat, Pembrolizumab - Prostate Cancer, Neuroendocrine Tumors | Phase 1 / Phase 2 | Completed | BioXcel Therapeutics Inc | 97 | 2019-06-10 | 2026-11-10 |
| Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Laboratory Biomarker Analysis, Pembrolizumab, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 157 | 2016-08-15 | 2026-07-17 |
| RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) RRx-001, Cisplatin, Etoposide - Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | EpicentRx, Inc. | 139 | 2015-06-01 | 2025-03-17 |
| Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Cisplatin, Etoposide, Veliparib - Extensive Stage Small Cell Lung Carcinoma, Large Cell Lung Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 156 | 2012-09-28 | 2026-06-24 |
| Hypofractionated Radiotherapy for Limited Stage Small Cell Lung Cancer Hypofractionated Chest Radiotherapy - Lung Neoplasm, Small Cell Carcinoma | Phase 2 | Completed | AHS Cancer Control Alberta | 2 | 2009-06-01 | 2016-02-22 |
Carcinoma, Small Cell (9) · Small Cell Lung Carcinoma (6) · Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (2) · Neuroendocrine Tumors (2) · Prostatic Neoplasms (2) · Adrenal Cortex Neoplasms (1) · Anus Neoplasms (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms, Unknown Primary (1)
Carcinoma (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms by Site (9) · Neoplasms, Glandular and Epithelial (9) · Bronchial Neoplasms (7) · Carcinoma, Bronchogenic (7) · Lung Diseases (7) · Respiratory Tract Diseases (7) · Respiratory Tract Neoplasms (7) · Thoracic Neoplasms (7) · Genital Diseases (5) · Lung Neoplasms (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Nerve Tissue (5)
Cisplatin (2) · Etoposide (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · Carboplatin (1) · Gemcitabine (1) · Irinotecan (1) · PT-100 dipeptide (1) · Paclitaxel (1) · Pemetrexed (1) · Penfluridol (1) · Platinum (1) · Podophyllotoxin (1) · RRx-001 (1) · Vinorelbine (1)
National Cancer Institute (NCI) (2) · AHS Cancer Control Alberta (1) · BioXcel Therapeutics Inc (1) · EpicentRx, Inc. (1) · M.D. Anderson Cancer Center (1) · MacroGenics (1) · Rahul Aggarwal (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
United States (7) · United Kingdom (2) · Australia (1) · Belgium (1) · Canada (1) · China (1) · France (1) · Italy (1) · Poland (1) · South Korea (1) · Spain (1)
Anish Thomas, M.D. (1) · Aung Naing (1) · Bryan Oronsky, MD, PhD (1) · Liudmila Schafer, M.D. (1) · Peng Wu, PhD (1) · Rahul Aggarwal, MD (1) · Taofeek Owonikoko (1)
PMID 30523756, PMID 31231122, PMID 31533818, PMID 32188704, PMID 32303619, PMID 32534809, PMID 32860331, PMID 33415580, PMID 33427689, PMID 33491277, PMID 33569311, PMID 33770291, PMID 34241781, PMID 34725215, PMID 35618285, PMID 35999229, PMID 37568622, PMID 40212844, PMID 41143139, PMID 42114950, PMID 42342409
U10CA021115 (1), U10CA180820 (1), U24CA196172 (1)